Alam Rahat, Imon Raihan Rahman, Kabir Talukder Md Enamul, Akhter Shahina, Hossain Md Alam, Ahammad Foysal, Rahman Md Mashiar
Molecular and Cellular Biology Laboratory, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology Jashore-7408 Bangladesh
Laboratory of Computational Biology, Biological Solution Centre (BioSol Centre) Jashore-7408 Bangladesh
RSC Adv. 2021 Dec 17;11(63):40120-40135. doi: 10.1039/d1ra06842c. eCollection 2021 Dec 13.
SARS-CoV-2 is an etiologic agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. The virus has rapidly extended globally and taken millions of lives due to the unavailability of therapeutics candidates against the virus. Till now, no specific drug candidates have been developed that can prevent or treat infections caused by the pathogen. The main protease (M) of the SARS-CoV-2 plays a pivotal role in mediating viral replication and mechanistically inhibition of the protein can hinder the replication and infection process of the virus. Therefore, the study aimed to identify the natural bioactive compounds against the virus that can block the activity of the M and subsequently block viral infections. Initially, a total of 96 phytochemicals from Poir. and (L.) Roxb. plants were identified through the gas chromatography-mass spectrometry (GC-MS) analytical method. Subsequently, the compounds were screened through molecular docking, absorption, distribution, metabolism, excretion (ADME), toxicity (T), and molecular dynamics (MD) simulation approach. The molecular docking method initially identified four molecules having a PubChem CID: 70825, CID: 25247358, CID: 54685836 and, CID: 1983 with a binding affinity ranging between -6.067 to -6.53 kcal mol to the active site of the target protein. All the selected compounds exhibit good pharmacokinetics and toxicity properties. Finally, the four compounds were further evaluated based on the MD simulation methods that confirmed the binding stability of the compounds to the targeted protein. The computational approaches identified the best four compounds CID: 70825, CID: 25247358, CID: 54685836 and, CID: 1983 that can be developed as a treatment option of SARS-CoV-2 disease-related complications. Although, experimental validation is suggested for further evaluation of the work.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是导致2019年冠状病毒病(COVID-19)大流行的病原体。由于缺乏针对该病毒的治疗候选药物,该病毒已在全球迅速传播并夺走了数百万人的生命。到目前为止,尚未开发出能够预防或治疗由该病原体引起的感染的特定候选药物。SARS-CoV-2的主要蛋白酶(M)在介导病毒复制中起关键作用,从机制上抑制该蛋白可阻碍病毒的复制和感染过程。因此,该研究旨在鉴定针对该病毒的天然生物活性化合物,这些化合物可阻断M的活性并随后阻断病毒感染。最初,通过气相色谱-质谱(GC-MS)分析方法从Poir.和(L.)Roxb.植物中总共鉴定出96种植物化学物质。随后,通过分子对接、吸收、分布、代谢、排泄(ADME)、毒性(T)和分子动力学(MD)模拟方法对这些化合物进行筛选。分子对接方法最初鉴定出四个分子,其PubChem CID分别为:70825、25247358、54685836和1983,与靶蛋白活性位点的结合亲和力在-6.067至-6.53 kcal/mol之间。所有选定的化合物均表现出良好的药代动力学和毒性特性。最后,基于MD模拟方法对这四种化合物进行了进一步评估,证实了这些化合物与靶蛋白的结合稳定性。这些计算方法确定了四种最佳化合物CID:70825、25247358、54685836和1983,它们可被开发为治疗SARS-CoV-2疾病相关并发症的选择。不过,建议进行实验验证以进一步评估该研究成果。